This systems-level approach revealed converging pathways in metabolism, cytoskeleton remodeling, and EMT, providing a roadmap for rational therapeutic targeting in BAG5-high NSCLC cases. The gene discussed is BAG5; the disease is non-small cell lung carcinoma.